Pattern of anti diabetic drug prescription at a health facility in Jos north central Nigeria by Uwakwe, J.N. et al.
59Jos Journal of Medicine, Volume 9  No. 1
PATTERN OF ANTI DIABETIC DRUG PRESCRIPTION AT A HEALTH 
FACILITY   IN JOS NORTH CENTRAL NIGERIA
Uwakwe J. N.  Agboghoroma O.F   Akanbi F.O  Odoh G.   Puepet F.H
Corresponding author: Dr Uwakwe Jones N.
Department of Internal Medicine, Jos University Teaching Hospital P M B 2076, Jos. Email: 
uwakwejones@yahoo.com
ABSTRACT
Introduction:  Type 2 diabetes mellitus is a disorder that can be managed with oral or parenteral 
medications. Oral agents are of different classes while insulin is the commonest parenteral agent. The 
choice of drug regimen is influenced by a variety of factors. This study aims to describe the pattern of anti 
diabetic drug prescription at a private health facility in North Central Nigeria.
Methodology: this was a retrospective study in which the records of 120 patients with Type 2 diabetes 
visiting the facility were reviewed and analyzed
Results: 64.2% of the study population were males. The mean ages for males and females were 54.2+/-8.4 
and  54.3+/-10.4 years respectively with no significant difference. Majority of subjects (75%) were 
receiving polytherapy, the commonest combination being biguanide + sulphonylurea. Only 2.5% were 
receiving insulin alone.
Conclusion: Anti diabetic treatment regimen should be guided by laid down guidelines and 
recommendations. It should also be individualized, as no two persons with Type 2 diabetes are exactly the 
same.
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INTRODUCTION
Type 2 diabetes mellitus is a chronic metabolic 
disorder characterized by hyperglycaemia. Its 
prevalence is rising at a significant rate in both 
developed and developing countries. It is projected 
that by  the year 2025 there will be 380 million 
persons worldwide with diabetes mellitus and 418 
million persons with other forms of impaired 
1
glucose intolerance . In the United States, it is 
estimated that as at the year 2000, 11 million 
Americans had diabetes mellitus, and that figure is 
2expected to rise to 29  million by 2050 . In Nigeria, 
the prevalence of Non Communicable Diseases 
such as diabetes mellitus has almost exceeded the 
prevalence of communicable diseases, as a result of 
factors such as an aging population and rapid 
3
urbanization . A review of endocrine-related 
admissions and mortality at a tertiary health centre 
in South Western Nigeria showed diabetes mellitus 
4to be the leading cause  . The World Health 
Organization estimates  Nigeria to have the highest 
number of persons with diabetes mellitus in 
5Africa . The burden of this disease places a great 
strain on the resources of countries. Diabetic 
patients cost twice as much to manage than non-
6
diabetics . A significant proportion of this cost is 
seen in the need to procure anti-diabetic 
medications which are often taken for life.  These 
medications may be orally or parenterally 
administered. Oral medications include the 
sulphonylureas, biguanides, thiazolidenediones, 
meglitinides, alpha-glucodidase inhibitors and 
Dipeptidylpeptidase IV inhibitors. Parenteral 
agents include insulin and others such as incretin 
analogues and amylin analogues. In addition to 
7 8
pharmacotherapy, diet therapy  and exercise  are 
other important aspects in the management of the 
disease.
OBJECTIVES
This study looks at the different classes and 
combinations of anti diabetic drugs prescribed for 
diabetic patients and their relationship with the 
duration of the disease.
MATERIALS AND METHODS
The records of 120 patients with Type 2 diabetes 
mellitus accessing care at a private health facility in 
Jos, North Central Nigeria between January and 
December 2009 were reviewed. Data obtained were 
age, sex, duration of diagnosis of diabetes, class and 
combination of anti diabetic medication being 
prescribed.
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STATISTICAL ANALYSIS
This was done using the Epi Info statistical 
software ( version 7.0 ). Quantitative variables ( age 
) were expressed as means while categorical 
variables ( sex, drug class ) were expressed as 
proportions. The students t test was used in the 
comparison of means. The Mood's test for 
comparison of medians was used for data with 
skewed distribution ( disease duration ). In all 
cases, p value < 0.05 was considered statistically 
significant.
RESULTS
The study population comprised 64.2% males and 
35.8% females. Mean ages of male and female  
subjects were  54.2+/-8.4 years and 54.3+/-10.4 
years respectively. There was no statistically 
significant difference between the two groups ( p = 
0.95 ). 25% of patients were receiving monotherapy 
and 75% polytherapy. 4.2% received biguanides ( 
metformin ) alone, 18.3%  sulphonylurea alone ( 
glimepiride mainly, less commonly glibenclamide 
), 60.8%   biguanide + sulphonylurea, 3.3%  
biguanide + sulphonylurea + thiazolidenedione ( 
pioglitazone ), 10.8%  biguanide + insulin, and 
2.5% were receiving insulin alone. Overall, 13.3% 
were receiving an insulin containing regimen ( 
insulin + metformin or insulin alone ) and 86.7% an 
insulin free regimen.
















































Table 1: distribution of the different treatment 
regimens
The median disease duration for those receiving 
insulin containing regimen was 7 years and that for 
those receiving insulin free regimen was 4 years. 
No statistically significant difference existed 
between the two using the Mood's test for 
2comparing medians ( X  = 3.08; df = 1; p = 0.07 ) 
DISCUSSION
The pattern of prescription of anti diabetic 
medications exhibits variations depending on the 
population being studied. In this study, we found 
out that the use of sulphonylurea alone was the 
commonest form of monotherapy, followed by 
monotherapy using biguanide alone and then 
insulin alone. No one was receiving monotherapy 
using a thiazolidenedione. Similar results were 
9,10obtained by other workers on the same subject . 
11
Guidoni et al  who also found sulphonylurea to be 
the commonest form of monotherapy prescribed for 
diabetics, observed glibenclamide to be the most 
frequently prescribed sulphonylurea. Our findings 
however, showed glimepiride to be the most 
frequently prescribed. There are studies that do not 
support the finding that sulphonylureas are the most 
frequently prescribed form of monotherapy in 
diabetic patients. They found biguanides ( precisely 
metformin ) to be the most frequently used  form of 
12,13
monotherapy . The reasons for the differences in 
the preferred choice of monotherapy is not entirely 
clear, but may be due to factors such as patient's 
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choice, patient characteristics ( for example, a 
biguanide would usually be preferred to a 
sulphonylurea in an individual who is obese ) or 
even the manufacturers of the pharmaceutical 
agent being used. In our study population, 
biguanide + sulphonylurea was the commonest 
combination therapy. This is what is obtained in 
14
some other populations . We also found out that 
thiazolidenediones were not a commonly 
prescribed anti diabetic agent, a finding shared by 
9,14some other authors . Thiazolidenediones are 
relatively new compared to other anti diabetic 
agents. They were introduced a little less than 20 
15
years ago . The popularity of the use of these 
agents by clinicians will probably grow over time 
as they acquire more experience with the use of 
these agents. 
It is understandable why only a small proportion of 
our study population (13.3%) were receiving an 
insulin containing regimen considering the fact 
that they all have Type 2 diabetes and not Type 1 
diabetes ( were the use of insulin is a necessity ).  In 
the United States, it was reported that from 1995 to 
2007, a survey showed a gradual decline in the use 
16of insulin among persons with Type 2 diabetes . 
The fact however is that majority of type 2 
diabetics will be unable to achieve or sustain 
normoglycaemia without the introduction of 
insulin at some point in their treatment, either as 
monotherapy or in conjunction with other oral 
17agents . This is due to the inevitable gradual 
decline in beta cell function in these individuals. 
Addition of insulin to oral agents in Type 2 diabetes 
has been shown to improve glycaemic control and 
18
reduce the risk of microvascular complications . It 
will be expected that the duration of diagnosis of 
diabetes  will be significantly longer in those on an 
insulin containing regimen than in those yet to 
commence an insulin containing regimen. This is  
based on the earlier argument that insulin will 
eventually be required over time in type 2 diabetes. 
We did not find any statistically significant 
difference between the duration of disease in the 
two groups. This could probably be explained by 
the fact that the information on the time of 
diagnosis of diabetes given by the patient does not 
necessarily correspond to the actual duration of the 
disease since type 2 diabetes is often present 
asymptomatically long before it is actually 
diagnosed.   
CONCLUSION
There are guidelines and recommendations by 
different national and international scientific 
bodies on the choices of anti diabetic medications to 
be used in the management of diabetes. Physicians 
should strike the delicate balance of complying with 
these recommendations and at the same time 
administering agents based on individual needs of 
patients. This is because no two persons with type 2 
diabetes are exactly the same.
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